Download PDF
Semin Thromb Hemost 2001; 27(2): 161-168
DOI: 10.1055/s-2001-14076
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Diagnosis and Management of Acute Obstetrical DIC

Takao Kobayashi1 , Toshihiko Terao1 , Masahiro Maki2 , Tsuyomu Ikenoue3
  • 1Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Japan
  • 2Department of Obstetrics and Gynecology, Akita University School of Medicine, Japan
  • 3Department of Obstetrics and Gynecology, Miyazaki Medical College, Japan
Further Information

Publication History

Publication Date:
31 December 2001 (online)

    Permissions and Reprints

ABSTRACT

Obstetrical disseminated intravascular coagulation (DIC) is usually a very acute, serious complication of pregnancy. The DIC diagnostic criteria in obstetrics (the obstetrical DIC score) help with making a prompt diagnosis and starting treatment early. These DIC diagnostic criteria, in which higher scores are given for clinical parameters than for laboratory parameters, have three components: (1) the underlying disease, (2) clinical symptoms, and (3) laboratory findings. It is justified that it is appropriate to initiate therapy for DIC when the obstetrical DIC score reaches 8 points or more before obtaining the results of coagulation tests. Management: (1) Control of the underlying disease: because prolongation of exposure to the triggering factors worsens DIC, it is important to eliminate the etiologic factors as rapidly as possible. Elimination of the cause of DIC can be easily performed in obstetrics, for example, by cesarean section. (2) Antithrombin (AT) therapy: AT monotherapy (1500 to 3000 units/day, 2 days) is preferably employed instead of heparin monotherapy or heparin-AT therapy because of the hemorrhagic side effects of heparin. (3) Synthetic serine protease inhibitors: continuous infusion of gabexate mesilate (FOY℗) or nafamostat mesilate (FUT℗) is effective for DIC. Controlled multicenter trials showed a significant improvement not only in clinical response but also in platelet counts and prothrombin time (PT) in the AT group compared with the FOY group. (4) Activated protein C (APC) can inhibit thrombin generation and accelerate fibrinolytic activity. APC (5000 to 10,000 units) is administered for 2 days in patients with placental abruption complicated by DIC. APC is a very safe, effective, and useful agent for the treatment of DIC.

KEYWORD

DIC diagnostic criteria in obstetrics - consumptive coagulopathy - underlying disease - antithrombin - activated protein C

REFERENCES

  • 1 Maki M. Antithrombin III: Recent advances in obstetrical disseminated intravascular coagulation.  Biomed Prog . 1992;  5 5-8
    PubMedGoogle Scholar
  • 2 Cunningham F G, MacDonald P C, Gaul N F. Hypovolemic shock and disseminated intravascular coagulation. In: Williams Obstetrics 20th ed. Stamford, CT: Appleton & Lange 1997: 783-796
    Google Scholar
  • 3 Terao T, Maki M, Ikenoue T. A prospective study in 38 patients with abruptio placentae of 70 cases complicated by DIC.  Asia Oceania J Obstet Gynaecol . 1987;  13 1-13
    PubMedGoogle Scholar
  • 4 Kobayashi N, Maekawa T, Takada M. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the research committee on DIC in Japan. In: Abe T, Yamanaka M, eds. Disseminated Intravascular Coagulation Tokyo: University of Tokyo Press 1983: 265-275
    Google Scholar
  • 5 Seegers W H. Antithrombin III, theory and clinical applications.  Am J Clin Pathol . 1973;  69 367-374
    PubMedGoogle Scholar
  • 6 Rosenberg R D. Heparin, antithrombin, and abnormal clotting.  Annu Rev Med . 1978;  29 367-378
    CrossrefPubMedGoogle Scholar
  • 7 Maki M, Terao T, Ikenoue T. Evaluation of therapeutic effects of antithrombin III concentrate for obstetrical DIC by multicenter clinical trial.  Jpn J Obstet Gynecol Neonat Hematol . 1994;  4 37-49
    PubMedGoogle Scholar
  • 8 Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin.  Biochim Biophys Acta . 1981;  661 342-345
    PubMedGoogle Scholar
  • 9 Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system.  Haemostasis . 1985;  15 164-168
    PubMedGoogle Scholar
  • 10 Maki M, Terao T, Ikenoue T. Clinical evaluation of antithrombin III concentrate (BI6.013) for disseminated intravascular coagulation in obstetrics.  Gynecol Obstet Invest . 1987;  23 230-240
    PubMedGoogle Scholar
  • 11 Sakata Y, Curriden S, Lawrence D. Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity.  Proc Natl Acad Sci USA . 1985;  82 1121-1125
    PubMedGoogle Scholar
  • 12 Kobayashi T, Terao T, Maki M, Ikenoue T. Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption (Letter).  Thromb Haemost . 1999;  82 1363
    PubMedGoogle Scholar
  • 13 Page E W, King E B, Merrill J A. Abruptio placentae: dangers of delay in delivery.  Obstet Gynecol . 1954;  3 385-393
    PubMedGoogle Scholar
  • 14 Lasch H G, Heene D H. Heparin therapy of diffuse intravascular coagulation (DIC).  Thromb Diath Haemorrh . 1975;  33 105-106
    PubMedGoogle Scholar
  • 15 Marciniak E, Gockerman J P. Heparin-induced decrease in circulating antithrombin III.  Lancet . 1977;  2 581-584
    PubMedGoogle Scholar
  • 16 Klein H G, Bell W R. Disseminated intravascular coagulation during heparin therapy.  Ann Intern Med . 1974;  80 447-481
    PubMedGoogle Scholar
  • 17 Kobayashi H, Gotoh J, Fujie M. Urinary trypsin inhibitor protects neutrophil chemotaxis in the inflammatory response.  Int J Oncol . 1995;  7 817-823
    PubMedGoogle Scholar